← Back to all signals
RESEARCH PAPER ANALYSIS

The phase average wavelength of alpha rhythm in EEG signals of patients with Parkinson's disease combined with cognitive impairment.

PD patients show a prolonged phase-average wavelength of alpha EEG rhythm—greater in those with cognitive impairment—and this measure correlates negatively with cognitive test scores.

PMID42018511
JournalPloS one
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

PD patients show a prolonged phase-average wavelength of alpha EEG rhythm—greater in those with cognitive impairment—and this measure correlates negatively with cognitive test scores.

WHY IT MATTERS

Research significance

Identifies a noninvasive EEG biomarker that could help detect and track cognitive decline and stratify patients in clinical studies, offering translational utility for outcome measurement though it does not directly inform molecular therapeutic targets.

ABSTRACT

Source abstract

OBJECTIVE: To investigate the changes of phase average wavelength of alpha rhythm in different brain regions of patients with Parkinson's Disease (PD) during awake period with eyes closed. METHODS: This study included 54 patients with PD and 30 normal controls. The PD patients were divided into a PD-cognitive normal group (PD-NC) and a PD-cognitive impairment group (PD-CI) based on Mini-Mental State Examination (MMSE) scores. The electroencephalography signals were decomposed at different scales using the Gauss continuous wavelet transform method. The phase average wavelength of the ninth scale (corresponding to the alpha rhythm) was extracted using the conditional sampling and phase averaging method. The alpha-band wavelengths of the background rhythm of different leads were compared between groups. Additionally, the correlation between the wavelength of the ninth scale and MMSE and Montreal Cognitive Assessment (MoCA) scores in PD patients was analyzed. RESULTS: There were significant differences in phase average wavelength at scale nine in each lead among the three groups (P < 0.05). The phase average wavelength of the alpha rhythm in all brain regions corresponding to the ninth scale in PD patients was prolonged compared with the normal controls (P < 0.05). There was a tendency for the PD-CI group to be longer than the PD-NC group, especially in the frontal area, central area and anterior temporal area. The average wavelength of alpha rhythm phase was negatively correlated with MoCA score in PD patients in all leads (P < 0.05), except the right central region (C4) and middle temporal region (T4). CONCLUSIONS: The phase average wavelength of the alpha rhythm in PD patients was longer than that in normal controls, indicating that the alpha rhythm of PD patients was slowed down. With the deterioration of cognitive function, the alpha rhythm of PD patients gradually slowed down. SIGNIFICANCE: The phase average wavelength of the electroencephalography alpha rhythm may become a new parameter for the evaluation of cognitive impairment.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic